UBS Reiterates Buy Rating on BridgeBio Pharma (BBIO), Optimistic on Encaleret
Tweet Send to a Friend
UBS analyst Eliana Merle reiterated a Buy rating and $72.00 price target on BridgeBio Pharma (NASDAQ: BBIO).The analyst commented, "BBIO ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
